Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.

Liau JY, Tsai JH, Yang CY, Lee JC, Liang CW, Hsu HH, Jeng YM.

Hum Pathol. 2015 Sep;46(9):1360-6. doi: 10.1016/j.humpath.2015.05.019. Epub 2015 Jun 5.

PMID:
26190196
2.

Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.

Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH, Yang CY.

Am J Surg Pathol. 2015 Feb;39(2):236-44. doi: 10.1097/PAS.0000000000000324.

PMID:
25229770
3.

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Liau JY, Lee JC, Tsai JH, Yang CY, Liu TL, Ke ZL, Hsu HH, Jeng YM.

Mod Pathol. 2015 Dec;28(12):1545-54. doi: 10.1038/modpathol.2015.114. Epub 2015 Oct 2.

4.

Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.

Lee JC, Jeng YM, Liau JY, Tsai JH, Hsu HH, Yang CY.

Mod Pathol. 2015 Aug;28(8):1064-73. doi: 10.1038/modpathol.2015.67. Epub 2015 May 29.

5.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A.

Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.

PMID:
24148618
6.

Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.

VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM.

Cancer Cytopathol. 2017 Jul;125(7):544-551. doi: 10.1002/cncy.21857. Epub 2017 Apr 3.

7.

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE.

Mod Pathol. 2012 Jul;25(7):1033-9. doi: 10.1038/modpathol.2012.53. Epub 2012 May 11.

8.

Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.

Kim HS, Lee HS, Nam KH, Choi J, Kim WH.

Anticancer Res. 2015 Jun;35(6):3501-10.

PMID:
26026117
9.

Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas.

Panse G, Chrisinger JS, Leung CH, Ingram DR, Khan S, Wani K, Lin H, Lazar AJ, Wang WL.

Histopathology. 2018 Jan;72(2):239-247. doi: 10.1111/his.13337. Epub 2017 Oct 19.

PMID:
28796347
10.

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.

Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, Perry A.

Mod Pathol. 2013 Nov;26(11):1425-32. doi: 10.1038/modpathol.2013.90. Epub 2013 Jun 14.

11.

Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.

Bower K, Napier CE, Cole SL, Dagg RA, Lau LM, Duncan EL, Moy EL, Reddel RR.

PLoS One. 2012;7(11):e50062. doi: 10.1371/journal.pone.0050062. Epub 2012 Nov 20.

12.

Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.

Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR.

J Neurooncol. 2019 May;142(3):435-444. doi: 10.1007/s11060-019-03127-w. Epub 2019 Mar 4.

PMID:
30830680
13.

Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.

Ahvenainen TV, Mäkinen NM, von Nandelstadh P, Vahteristo MEA, Pasanen AM, Bützow RC, Vahteristo PM.

Cancer. 2018 Dec 15;124(24):4650-4656. doi: 10.1002/cncr.31754. Epub 2018 Nov 13.

14.

TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.

Brügger F, Dettmer MS, Neuenschwander M, Perren A, Marinoni I, Hewer E.

J Neuropathol Exp Neurol. 2017 Jan 1;76(1):61-66. doi: 10.1093/jnen/nlw106.

PMID:
28040793
15.

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.

Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.

16.

ATRX represses alternative lengthening of telomeres.

Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, Reddel RR.

Oncotarget. 2015 Jun 30;6(18):16543-58.

17.

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.

Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, Bahary N, Brand RE, McGrath KM, Slivka A, Cressman KL, Fuhrer K, O'Sullivan RJ.

Clin Cancer Res. 2017 Jan 15;23(2):600-609. doi: 10.1158/1078-0432.CCR-16-1113. Epub 2016 Jul 12.

18.

Alternative lengthening of telomeres does exist in various canine sarcomas.

Kreilmeier T, Sampl S, Deloria AJ, Walter I, Reifinger M, Hauck M, Borst LB, Holzmann K, Kleiter M.

Mol Carcinog. 2017 Mar;56(3):923-935. doi: 10.1002/mc.22546. Epub 2016 Sep 22.

PMID:
27585244
19.

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P.

PLoS Genet. 2016 Feb 18;12(2):e1005850. doi: 10.1371/journal.pgen.1005850. eCollection 2016 Feb.

20.

Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.

Tang M, Li Y, Zhang Y, Chen Y, Huang W, Wang D, Zaug AJ, Liu D, Zhao Y, Cech TR, Ma W, Songyang Z.

J Cell Sci. 2015 Jan 15;128(2):331-41. doi: 10.1242/jcs.159467. Epub 2014 Nov 21.

Supplemental Content

Support Center